Biology validated.
Metabolic surgery established the intestine as a powerful regulator of whole-body metabolism.

Market validated.
GLP-1/GIP therapies demonstrated enormous demand for effective obesity pharmacotherapy.

Unmet need remains.
Persistence, tolerability, lean-mass preservation, chronic systemic exposure and heterogeneous response leave room for complementary approaches.

Technology ready.
Elaphron’s prior GI drug-development experience and locally acting platform create an opportunity to translate this biology pharmacologically.